首页> 美国卫生研究院文献>other >Dopamine Transport Inhibitors Based on GBR12909 and Benztropine as Potential Medications to Treat Cocaine Addiction
【2h】

Dopamine Transport Inhibitors Based on GBR12909 and Benztropine as Potential Medications to Treat Cocaine Addiction

机译:基于GBR12909和苯甲平的多巴胺转运抑制剂可能是治疗可卡因成瘾的药物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The discovery and development of medications to treat addiction and notably, cocaine addiction, have been frustrated by both the complexity of the disorder and the lack of target validation in human subjects. The dopamine transporter has historically been a primary target for cocaine abuse medication development, but addictive liability and other confounds of such inhibitors of dopamine uptake have limited clinical evaluation and validation. Herein we describe efforts to develop analogues of the dopamine uptake inhibitors GBR 12909 and benztropine that show promising profiles in animal models of cocaine abuse that contrast to that of cocaine. Their unique pharmacological profiles have provided important insights into the reinforcing actions of cocaine and we propose that clinical investigation of novel dopamine uptake inhibitors will facilitate the discovery of cocaine-abuse medications.
机译:疾病的复杂性和人类受试者缺乏靶标验证都使人们难以发现治疗成瘾特别是可卡因成瘾的药物。从历史上看,多巴胺转运蛋白一直是可卡因滥用药物开发的主要目标,但是这种多巴胺摄取抑制剂的成瘾性和其他混杂因素限制了临床评估和验证。本文中,我们描述了开发可卡因滥用动物模型中与可卡因相反的多巴胺摄取抑制剂GBR 12909和苯氧平的类似物的努力。他们独特的药理特性为可卡因的增强作用提供了重要的见识,我们建议对新型多巴胺摄取抑制剂进行临床研究将有助于发现可卡因滥用药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号